Research programme: epidermolysis bullosa therapeutics - Abeona TherapeuticsAlternative Names: AAV DJCOL7A1; EB-201
Latest Information Update: 23 Aug 2016
At a glance
- Originator Abeona Therapeutics
- Developer Abeona Therapeutics; Epidermolysis Bullosa Research Partnership; Stanford University
- Class Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Epidermolysis bullosa